Protocol Guide • Vitamin B1 • Updated 2026

Thiamine Mega-Dose
Protocol

High-dose Vitamin B1 for neurodegeneration, chronic disease, and mitochondrial restoration — all 4 forms, dosing tiers, paradoxical reaction warning, and required cofactors.

Inspired by Elliot Overton (@EO_Nutrition) · 15K+ viral engagements · Based on clinical research
0
% mean UPDRS score improvement in Parkinson's trial (Costantini et al., 2015)
0
Active thiamine forms: HCl, Benfotiamine, TTFD, Sulbutiamine
0
× greater bioavailability of benfotiamine vs. standard thiamine HCl

Why Mega-Dose B1?

Standard thiamine RDA (1.1–1.2mg/day) prevents classic deficiency. But pharmacological mega-dosing operates through an entirely different mechanism.

The "Functional Deficiency" Hypothesis

Chronic toxicity, oxidative stress, and inflammation can inactivate thiamine-dependent enzymes at the cellular level — producing a state called "functional thiamine deficiency" even when blood levels appear normal. Normal dietary levels simply cannot overcome this enzymatic blockade. Pharmacological concentrations are required to saturate and restore these deranged metabolic pathways. This theory, developed by Dr. Derrick Lonsdale and further popularized by Elliot Overton (EO Nutrition), explains why high-dose B1 shows broad benefits across seemingly unrelated conditions.

🔋

Mitochondrial Energy

Thiamine is a critical cofactor for pyruvate dehydrogenase (PDH) and α-ketoglutarate dehydrogenase — enzymes at the core of ATP production. Dysfunction → chronic fatigue, brain fog, metabolic collapse.

🧠

Neurological Protection

Thiamine deficiency produces selective damage to high-metabolic brain regions. Mega-dosing restores acetylcholine synthesis, reduces neuroinflammation, and supports myelin integrity.

🛡️

AGE Inhibition

Benfotiamine specifically activates transketolase, diverting glucose away from AGE-forming pathways. Directly relevant to diabetic complications, vascular aging, and neurodegeneration.

🌿

Autonomic Regulation

The autonomic nervous system is highly thiamine-dependent. Mega-dosing is used for dysautonomia, POTS, and vagal tone dysregulation — conditions often missed as "functional" issues.

🧬

Gene Expression

High-dose thiamine modulates gene expression related to energy metabolism, inflammatory cytokines, and oxidative stress — effects not achievable at nutritional doses.

💊

Exceptional Safety

Thiamine is water-soluble (forms HCl, benfotiamine, TTFD). Clinical trials report no serious adverse events even at multi-gram doses. Safety profile is one of the best among any B vitamin.

4 Active Thiamine Forms

Each form has distinct bioavailability, tissue distribution, and clinical applications. Choose based on your target condition.

Form Solubility Bioavailability BBB Crossing Best For Typical Dose
Thiamine HCl Water-soluble Baseline (1×) Limited Baseline / clinical trials, IV protocols 100–500mg/day
Benfotiamine
5–11× HCl
Fat-soluble (S-acyl) ~5–11× HCl Moderate Neuropathy, AGE inhibition, Alzheimer's, peripheral nerves 150–600mg/day
TTFD
Best CNS
Fat-soluble (disulfide) Very high Excellent ✅ Brain, autonomic NS, neurodegeneration, fatigue syndromes 25–100mg/day
Sulbutiamine
Nootropic
Fat-soluble (synthetic) High (lipophilic) Good ✅ Cognitive enhancement, mood, memory, fatigue (psychogenic) 200–600mg/day
Dibenzoylthiamine (DBT) Fat-soluble Very high Moderate Emerging — neuroprotection, strong antioxidant profile (research stage) TBD
💡
Protocol Tip: Stack TTFD + Benfotiamine

Advanced protocols often combine TTFD (for CNS/brain penetration) with benfotiamine (for peripheral nerve protection and AGE inhibition). Start with benfotiamine alone to assess tolerance, then introduce TTFD at low dose (25mg) before titrating up. This stacking approach provides complementary tissue coverage.

Bioavailability & CNS Penetration

Relative performance across the key metrics that determine clinical efficacy for neurological applications.

📊 Plasma Bioavailability (relative to Thiamine HCl = 100%)
Thiamine HCl
1× (baseline)
Benfotiamine
~5–11× HCl
TTFD
Very high (lipophilic)
Sulbutiamine
High (synthetic lipophilic)
🧠 Blood-Brain Barrier Penetration Score
Thiamine HCl
Poor — limited at high dose
Benfotiamine
Moderate — good peripheral
TTFD
Excellent — highest CNS delivery
Sulbutiamine
Good — nootropic effects

Start Low, Go Slow

The Overton/Lonsdale framework for escalating thiamine dosing — always with cofactors in place first. Individual variation is enormous; titration is mandatory.

T1

Phase 1: Foundation (Weeks 1–2)

Establish cofactor base before starting thiamine. This phase prevents paradoxical reactions and ensures enzymatic conversion is supported.

Magnesium glycinate 200mg/day + B-Complex + Potassium (dietary)
T2

Phase 2: Low Dose Start (Weeks 3–4)

Introduce thiamine at lowest effective dose. Monitor for paradoxical reaction (fatigue, anxiety, tachycardia, insomnia). If symptoms worsen, hold and ensure cofactors are adequate.

Benfotiamine 100–150mg/day OR TTFD 25–50mg/day (not both initially)
T3

Phase 3: Therapeutic Titration (Weeks 5–12)

Gradually increase dose every 1–2 weeks while monitoring symptoms. Clinical improvement often begins at 300–500mg benfotiamine or 50–100mg TTFD. May add Thiamine HCl for higher total thiamine load.

Benfotiamine 300–600mg/day OR TTFD 50–100mg/day + HCl 100–500mg
T4

Phase 4: Maintenance / High Protocol

Advanced protocols used for serious neurological conditions (Parkinson's, Alzheimer's). Typically supervised. Parkinson's trials used IV or oral thiamine 1–4g/day. Sustain cofactors throughout.

Thiamine HCl 500mg–4g/day (supervised) + benfotiamine 300–600mg + cofactors

The Paradoxical Reaction

The most important thing to understand about thiamine mega-dosing — and the most common reason people quit prematurely.

⚠️ Paradoxical Worsening: Real & Temporary

When thiamine begins to restore cellular energy metabolism, some individuals experience a temporary worsening of symptoms. This can manifest as increased fatigue, brain fog, anxiety, heart palpitations, insomnia, or general malaise. This is NOT an allergic reaction or sign of harm — it is a metabolic adjustment as cells ramp up ATP production after prolonged suppression. The reaction is more common with TTFD than benfotiamine due to faster CNS penetration.

🔍

Why It Happens

Restoring oxidative energy metabolism suddenly increases metabolic demand for cofactors (especially magnesium). A temporary "nutritional debt" is called in. Additionally, rapid restoration of autonomic nerve function can trigger transient dysautonomia symptoms.

🩺

How to Manage It

If reaction occurs: Hold dose for 1 week. Increase magnesium to 300–400mg/day. Ensure complete B-complex coverage. Resume at 50% of last dose. Titrate more slowly. Most reactions resolve within 1–3 weeks. Do NOT permanently stop — slow down instead.

📝
Start-Low-Go-Slow Is Not Optional

Overton's protocol specifically warns against starting at high doses. Beginning at 25mg TTFD or 100mg benfotiamine — rather than therapeutic doses immediately — dramatically reduces paradoxical reaction severity. Most people who experience severe paradoxical reactions jumped straight to 100mg+ TTFD or 500mg+ benfotiamine without cofactor priming.

What B1 Needs to Work

Thiamine cannot be activated or utilized without adequate cofactors. These are not optional additions — they are prerequisites.

🔴 Magnesium
200–400mg/day (glycinate or malate)
CRITICAL. Magnesium is a required cofactor for TPK (thiamine pyrophosphokinase), the enzyme that converts thiamine → ThDP (the active coenzyme form). Without adequate Mg, thiamine cannot be activated regardless of dose. Start Mg 2 weeks BEFORE thiamine.
🔴 B-Complex
Full-spectrum B-complex, 1–2×/day
CRITICAL. Thiamine works synergistically with all B vitamins — especially B2 (riboflavin), B3 (niacin), and B6. High-dose thiamine can deplete other B vitamins by competition. A high-quality B-complex prevents secondary deficiencies and supports the broader energy metabolism cascade.
🟡 Potassium
3,500–4,700mg/day (dietary) or 200–400mg supplement
As thiamine restores cellular metabolism, cells increase K+ uptake (similar to refeeding syndrome). Hypokalemia can mimic or worsen paradoxical reactions. Priority: dietary potassium (avocados, bananas, potatoes, leafy greens) over supplementation.
🩵 Alpha-Lipoic Acid
100–300mg/day
ALA directly supports the pyruvate dehydrogenase complex — the same enzyme system thiamine activates. Synergistic with benfotiamine for neuropathy and metabolic restoration. Also regenerates other antioxidants (vitamins C, E, glutathione).
🩵 Acetyl-L-Carnitine
500–1000mg/day
Supports mitochondrial function by facilitating fatty acid transport into mitochondria. Complements thiamine's role in energy metabolism. Demonstrated synergy with benfotiamine in neuropathy protocols.
🩵 Zinc
15–25mg/day (not with high-dose copper)
Required for several thiamine-dependent enzymatic processes. Also modulates NMDA receptor activity, relevant for the neuroprotective applications of thiamine mega-dosing.

What the Research Shows

Published peer-reviewed studies on high-dose thiamine in neurological conditions.

Long-Term Treatment with High-Dose Thiamine in Parkinson Disease: An Open-Label Pilot Study
2015
Costantini A, Pala MI, Grossi E, Mondonico S, Cardelli LE, Jenner C, Proietti S, Colangeli M, Fancellu R. | J Altern Complement Med. 2015 Dec;21(12):740-7. | PMID: 26505466
Key finding: 50 PD patients treated with high-dose IV or oral thiamine (1–4g/day). Mean UPDRS scores improved from 38.55 ± 15.24 to 18.16 ± 15.08 (p = 2.4 × 10⁻¹⁴) — approximately 52% improvement within 3 months. Plasma thiamine levels were within normal range at baseline in all patients (supporting the "functional deficiency" hypothesis). No adverse events reported.
↗ PubMed PMID: 26505466
Benfotiamine and Cognitive Decline in Alzheimer's Disease: Results of a Randomized Placebo-Controlled Phase IIa Clinical Trial
2020
Gibson GE, Luchsinger JA, Cirio R, et al. | J Alzheimers Dis. 2020;78(3):989-1010. | DOI: 10.3233/JAD-200896
Key finding: 12-month double-blind RCT of benfotiamine 600mg/day in mild Alzheimer's patients. Primary endpoint: CDR-SB scores increased 43% less in the treatment group vs. placebo, suggesting disease-modifying slowing. FDG-PET showed reduced metabolic decline. No significant adverse events at 600mg/day for 12 months.
↗ PubMed PMID: 33044178
Preliminary Findings of High-Dose Thiamine in Dementia of Alzheimer's Type
1993
Meador K, Loring D, Nichols M, et al. | J Geriatr Psychiatry Neurol. 1993;6(4):222-9. | PMID: 8251051
Key finding: Early pilot study using oral thiamine 3–8g/day in Alzheimer's patients over 3 months. Modest improvements in cognitive function measures observed. Established safety of gram-level oral thiamine. Catalyzed further research into thiamine deficiency's role in AD pathology.
↗ PubMed PMID: 8251051
Pharmacological Thiamine Levels as a Therapeutic Approach in Alzheimer's Disease
2022
Gibson GE, Xu H, Chen HL, et al. | Front Med (Lausanne). 2022;9:1033272. | DOI: 10.3389/fmed.2022.1033272
Key finding: Review synthesizing evidence for pharmacological thiamine in AD. Thiamine-dependent enzymes are consistently reduced in AD brains. Restoring these enzymes via pharmacological dosing reduces amyloid deposition, normalizes glucose metabolism, and reverses neuroinflammation in animal models. Phase II trial data supports clinical translation.
↗ Frontiers in Medicine
Neuroprotective Effects of Thiamine and Precursors with Higher Bioavailability: Focus on Benfotiamine and Dibenzoylthiamine
2021
Bettendorff L, et al. | Int J Mol Sci. 2021;22(11):5418. | PMC8196556
Key finding: Comprehensive review comparing thiamine and lipophilic derivatives for neuroprotection. Dibenzoylthiamine (DBT) emerges as a promising next-generation compound with strong antioxidant profile. Benfotiamine validated for peripheral nerve protection. TTFD highlighted for superior CNS delivery. Establishes the mechanistic rationale for derivative use over standard HCl.
↗ PMC8196556

Morning / Evening Split

Sample maintenance protocol (Phase 3+) for cognitive and neurological support. Adjust doses based on individual response and form selection.

🌅 Morning (with breakfast)
Benfotiamine 300mg — fat-soluble, take with food for absorption
TTFD 50mg — start lower; B1 form for CNS penetration
Magnesium glycinate 200mg — cofactor, take early to avoid GI later
B-Complex (1 capsule) — full B vitamin synergy
Alpha-Lipoic Acid 200mg — PDH complex cofactor, synergistic with B1
Zinc 15mg — enzymatic cofactor (take 2hr away from copper)
🌙 Evening (with dinner)
Benfotiamine 300mg — second dose for steady-state levels
Thiamine HCl 250mg — optional for higher total thiamine load
Magnesium glycinate 200mg — evening dose supports sleep + muscle
Acetyl-L-Carnitine 500mg — mitochondrial support, evening ok
Potassium 200mg — if dietary sources are low
⚠️ Avoid TTFD at night — stimulating effect can disrupt sleep
💰
Estimated Monthly Cost

Benfotiamine 600mg/day: ~$25–35/mo | TTFD 50mg/day (Thiamax): ~$35–50/mo | Magnesium glycinate: ~$15/mo | B-Complex: ~$10/mo | ALA 200mg: ~$12/mo | Total: approximately $95–120/month for the full maintenance stack.

Key Takeaways

✅ What the Evidence Supports

  • High-dose thiamine shows significant motor improvement in Parkinson's (52% UPDRS improvement, Costantini 2015)
  • Benfotiamine slowed cognitive decline 43% vs placebo in Alzheimer's Phase IIa RCT
  • TTFD provides superior CNS/brain penetration vs other forms
  • Safety profile is exceptional — no serious adverse events at multi-gram doses across multiple trials
  • Functional deficiency mechanism explains broad efficacy without classic deficiency markers
  • Cofactors (especially magnesium) are required for activation and must be taken concurrently
  • Start-low-go-slow with paradoxical reaction monitoring is effective harm reduction

⚠️ Limitations & Unknowns

  • Most thiamine neuroprotection studies are small, open-label, or pilot stage — Phase III RCTs needed
  • Optimal dosing for specific conditions is not yet standardized
  • Paradoxical reactions are real and can be severe without proper titration protocol
  • Sulbutiamine tolerance develops rapidly; not for daily long-term use as a nootropic
  • Dibenzoylthiamine is promising but largely research-stage with limited human data
  • No head-to-head comparison trials between thiamine forms for neurological endpoints
  • Mechanism of paradoxical reaction not fully elucidated in clinical literature

🛒 Recommended Products

Everything you need for a complete thiamine mega-dose protocol

Affiliate links help support MeetPeptide at no extra cost to you.

🔗 Related Research

Deep dives into each thiamine form and the full neuroprotection stack

📚

Want the Complete Protocol Guide?

Dosing schedules, interaction warnings, and cycle protocols for 50+ compounds — all in one place.


Get the Guide →
Educational Disclaimer: This page is for educational and informational purposes only. It is not medical advice. Thiamine (Vitamin B1) and its derivatives are dietary supplements in the United States. High-dose thiamine protocols described on this page are based on research and clinical case series; they are not FDA-approved treatments for any disease. Always consult with a qualified healthcare provider before beginning any supplementation protocol, especially if you have a neurological condition or are taking medications. Individual responses vary significantly. Data sourced from published peer-reviewed research; all claims linked to primary sources.